science
Mayo Clinic: Blood Marker May Predict Alzheimer's Risk in 5-10 Years

A blood test for a protein called p-tau217 may be able to flag a person's risk of cognitive decline five to 10 years before symptoms set in, according to a Mayo Clinic study reported by Fox News. The finding points toward a far less invasive screening option than the brain-imaging scans doctors currently rely on to detect Alzheimer's-related changes.
What did the Mayo Clinic study find?
Researchers at Mayo Clinic found that levels of p-tau217 in the blood correlated with the likelihood that an older adult would experience measurable cognitive decline in the following five to 10 years, according to Fox News' report on the research. The marker is already known to track with the buildup of amyloid plaques and tau tangles in the brain, the hallmark changes associated with Alzheimer's disease. The Mayo team's contribution was tying blood levels of the protein to a forward-looking window of risk, rather than only confirming disease that has already caused symptoms.
What is p-tau217 and why does it matter?
Tau is a protein that normally helps stabilize structures inside brain cells. In Alzheimer's disease, an abnormal, "phosphorylated" form of tau — including the variant known as p-tau217 — accumulates and is linked to the tangles that damage neurons over time. Because p-tau217 rises in the bloodstream as this process unfolds in the brain, it has become one of the most closely watched biomarkers in Alzheimer's research in recent years. A blood test that can detect it offers clinicians a way to look for early biological signs of the disease without a lumbar puncture or a brain scan.
How does this compare to PET scans?
Positron emission tomography, or PET, scans are the current clinical standard for visualizing amyloid and tau buildup directly in the brain. They are accurate but expensive, require specialized equipment, and expose patients to radioactive tracers. A blood draw is cheaper, faster, and can be done in a standard clinic or primary-care setting. Fox News' report frames the Mayo Clinic findings as evidence that the p-tau217 blood marker could serve as a less invasive stand-in for identifying people at elevated risk, rather than requiring every at-risk patient to undergo imaging.
Who should get tested, and what are the limits?
The source material does not specify an age range, risk-factor profile, or testing protocol for who should seek out a p-tau217 blood test, nor does it detail how a positive result should change a patient's care plan. Blood-based Alzheimer's markers are generally discussed by researchers as tools to help determine who might benefit from further evaluation — including imaging or specialist referral — rather than as a stand-alone diagnosis. The underlying research summarized by Fox News centers on risk prediction over a five-to-10-year horizon, not on diagnosing active disease at the time of the blood draw.
What happens next?
Biomarker research of this kind typically needs to move through larger validation studies and, eventually, regulatory review before a blood test can be adopted as routine screening in primary care. The Mayo Clinic findings, as reported, represent a step in demonstrating that p-tau217 levels carry predictive value over a multi-year window — information that could eventually help identify candidates for early intervention, lifestyle counseling, or enrollment in clinical trials testing Alzheimer's treatments before symptoms appear. Fox News' report does not indicate a timeline for broader clinical rollout.
By the numbers
- 5 years — the shorter end of the window during which elevated p-tau217 levels were associated with cognitive decline risk, per the Mayo Clinic findings.
- 10 years — the longer end of that predictive window, according to the same research.
The gap between those two figures underscores a point researchers routinely make about blood-based Alzheimer's markers: they describe a range of risk over time, not a precise countdown to symptom onset.
For readers tracking the broader shift toward blood-based neurological testing, the appeal is straightforward — a simple draw instead of a scan, and a risk estimate instead of a diagnosis. Whether that trade-off holds up in larger, more diverse patient populations is the question the next round of research will need to answer.
Questions
What is p-tau217?
It is a modified form of the tau protein that accumulates in the brain as part of the biological changes associated with Alzheimer's disease; it can also be detected through a blood test, according to Fox News' report on the Mayo Clinic research.
How far in advance can the blood test predict cognitive decline?
The Mayo Clinic study found that p-tau217 levels were associated with cognitive decline risk over a window of roughly five to 10 years, per Fox News.
Does the blood test replace a PET scan?
The source material frames it as a less invasive alternative for assessing risk, not an explicit replacement; PET scans remain the standard for directly imaging amyloid and tau in the brain.